Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies, yet achieving comparable efficacy against solid tumours remains a severe clinical challenge.

A primary obstacle is the immunosuppressive tumour microenvironment, which is characterised by high expression of inhibitory immune checkpoints like TIM-3 that aggressively induce T-cell exhaustion and promote tumour evasion.

While combining CAR-T cells with systemic checkpoint blockade antibodies is heavily investigated, it often leads to short-lived efficacy and severe immune-related adverse events. 

This new research, published in the Genes & Diseases journal by a team from Chongqing Medical University, The Ninth People's Hospital of Chongqing, Chongqing University Cancer Hospital and Sichuan University, investigated a safer, cell-intrinsic strategy by engineering HER2-specific CAR-T cells to simultaneously silence their own TIM-3 expression to combat solid ovarian tumours.

To directly counteract TIM-3-mediated immune evasion, the researchers constructed a dual-promoter lentiviral vector capable of simultaneously expressing a TIM-3-targeting short hairpin RNA (shRNA) and a third-generation CAR recognizing the HER2 antigen.

Flow cytometry confirmed that this dual genetic modification efficiently down-regulated TIM-3 without negatively altering the essential phenotype of the CAR-T cells, fundamentally maintaining a high proportion of potent central memory T cells.

Extensive in vitro co-culture experiments utilising Galectin-9-expressing human ovarian cancer (SKOV3) cells demonstrated the functional superiority of this advanced design.

The data conclusively revealed that TIM-3-silenced CAR-T cells exhibited profoundly higher lytic cytotoxicity, secreting significantly elevated levels of the critical anti-tumour cytokines IFN-γ and TNF-α compared to standard HER2-CAR-T cells.

Remarkably, in vivo evaluations using an ovarian cancer xenograft model demonstrated that the adoptive transfer of TIM-3-silenced CAR-T cells significantly delayed tumour growth and sharply minimized tumour burden during the early treatment phase compared to conventional CAR-T cells.

Because the TIM-3 blockade was localised entirely within the engineered T cells at the tumour site, this strategy inherently bypasses the systemic toxicities associated with injected monoclonal antibodies. 

However, researchers observed that the dramatic anti-tumour effect gradually diminished in the later stages of the trial.

Comprehensive RNA-sequencing and gene set variation analysis (GSVA) unraveled the underlying adaptive resistance mechanism, revealing that the delayed loss of efficacy was fundamentally driven by a massive compensatory up-regulation of the PD-1 signaling pathway and macrophage activation.

In conclusion, intrinsically targeting the TIM-3 checkpoint offers a powerful new strategy to temporarily shield CAR-T cells from early exhaustion and enhance localised target cell lysis.

This profound finding directly positions the development of dual-silenced CAR-T cells—simultaneously knocking down both TIM-3 and PD-1—as highly compelling, next-generation immunotherapies capable of delivering durable clinical remissions for solid tumours.

Source: Compuscript Ltd